A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer

Journal of Nuclear Medicine

Volumn 54, Issue 12, 2013, Pages 2132-2138

  Liu, Yang ^a,b   Hu, Xiang ^b   Liu, Hongguang ^b   Bu, Lihong ^b   Ma, Xiaowei ^b   Cheng, Kai ^b   Li, Jinbo ^b   Tian, Mei ^a   Zhang, Hong ^a   Cheng, Zhen ^b  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Bombesin; GRPR; PET; Prostate cancer

Indexed keywords

ALUMINUM FLUORIDE; AMBA PEPTIDE; BOMBESIN DERIVATIVE; COPPER 64; GASTRIN RELEASING PEPTIDE RECEPTOR; RM1 PEPTIDE; UNCLASSIFIED DRUG; 1-(1,3-CARBOXYPROPYL)-4,7-CARBOXYMETHYL-1,4,7-TRIAZACYCLONONANE; ACETIC ACID DERIVATIVE; BOMBESIN; COPPER; FLUORINE; SINGLE HETEROCYCLIC RINGS; 1 (1,3 CARBOXYPROPYL) 4,7 CARBOXYMETHYL 1,4,7 TRIAZACYCLONONANE; DIAGNOSTIC AGENT; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BIOASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOLECULAR IMAGING; MOLECULAR PROBE; MOLECULAR STABILITY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RADIOCHEMISTRY; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CELL TRANSFORMATION; CHEMISTRY; DIAGNOSTIC USE; DRUG STABILITY; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; SCINTISCANNING; TUMOR CELL LINE; 18F-ALF; GRPR; METHODOLOGY; PET;

ACETATES; ANIMALS; BOMBESIN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COPPER RADIOISOTOPES; DRUG STABILITY; FLUORINE RADIOISOTOPES; HETEROCYCLIC COMPOUNDS, 1-RING; ISOTOPE LABELING; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOCHEMISTRY;

18F-ALF; BOMBESIN; GRPR; PET; PROSTATE CANCER;

EID: 84893350355     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.121533     Document Type: Article

References (38)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Grant K, Lindenberg ML, Shebel H, et al. Functional and molecular imaging of localized and recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40 (suppl 1):S48-59.
3. Jana S, Blaufox MD. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med. 2006;36:51-72.
4. Bouchelouche K, Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol. 2008;179:34-45.
5. Larson SM, Schoder H. Advances in positron emission tomography applications for urologic cancers. Curr Opin Urol. 2008;18:65-70.
6. Oehr P, Bouchelouche K. Imaging of prostate cancer. Curr Opin Oncol. 2007; 19:259-264.
7. Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274-292.
8. Delgado Bolton RC, Mucientes Rasilla J, Perez Castejon MJ, Carreras Delgado JL. Positron emission tomography (PET) and PET-CT in renal, bladder and prostate cancer: update [in Spanish]. Actas Urol Esp. 2009;33:11-23.
9. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152-1159.
10. Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev. 2008;60:1-42.
11. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol. 1999;155:2067-2076.
12. Bostwick DG, Roth KA, Evans CJ, Barchas JD, Bensch KG. Gastrin-releasing peptide, a mammalian analog of bombesin, is present in human neuroendocrine lung tumors. Am J Pathol. 1984;117:195-200.
13. Johnson CV, Shelton T, Smith CJ, et al. Evaluation of combined 177Lu-DOTA-8- AOC-BBN (7-14)NH2 GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm. 2006;21:155-166.
14. Smith CJ, Volkert WA, Hoffman TJ. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol. 2005;32:733-740.
15. Ananias HJ, de Jong IJ, Dierckx RA, van de Wiele C, Helfrich W, Elsinga PH. Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals. Curr Pharm Des. 2008;14:3033-3047.
16. Abd-Elgaliel WR, Gallazzi F, Garrison JC, et al. Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector. Bioconjug Chem. 2008;19:2040-2048.
17. Garrison JC, Rold TL, Sieckman GL, et al. Evaluation of the pharmacokinetic effects of various linking group using the In-111-DOTA-X-BBN(7- 14)NH2 structural paradigm in a prostate cancer model. Bioconjug Chem. 2008;19:1803-1812.
18. Prasanphanich AF, Nanda PK, Rold TL, et al. [64Cu-NOTA-8-Aoc-BBN(7-14) NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci USA. 2007;104:12462-12467.
19. Xu Y, Huang W, Ren G, et al. A four-arma star-shaped poly(ethylene glycol) (StarPEG) platform for bombesin peptide delivery to gastrin-releasing peptide receptors in prostate cancer. ACS Macro Letters. 2012;1:753-757.
20. Graham MM, Menda Y. Radiopeptide imaging and therapy in the United States. J Nucl Med. 2011;52(suppl 2):56S-63S.
21. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide imaging and therapy in Europe. J Nucl Med. 2011;52(suppl 2):42S-55S.
22. Ait-Mohand S, Fournier P, Dumulon-Perreault V, et al. Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates. Bioconjug Chem. 2011;22:1729-1735.
23. Lantry LE, Cappelletti E, Maddalena ME, et al. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med. 2006;47:1144-1152.
24. Mansi R, Wang X, Forrer F, et al. Evaluation of a 1,4,7,10- tetraazacyclododecane- 1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res. 2009;15:5240-5249.
25. Schroeder RP, van Weerden WM, Krenning EP, et al. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. Eur J Nucl Med Mol Imaging. 2011;38:1257-1266.
26. Ho CL, Liu IH,Wu YH, et al. Molecular imaging, pharmacokinetics, and dosimetry of In-AMBA in human prostate tumor-bearing mice. J Biomed Biotech. 2011;2011: 101497.
27. Lane SR, Nanda P, Rold TL, et al. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [Cu-64-NO2A- (X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model. Nucl Med Biol. 2010;37:751-761.
28. Maddalena ME, Fox J, Chen J, et al. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med. 2009;50:2017-2024.
29. Anderson CJ, Ferdani R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm. 2009;24:379-393.
30. Laverman P, McBride WJ, Sharkey RM, et al. A novel facile method of labeling octreotide with 18F-fluorine. J Nucl Med. 2010;51:454-461.
31. McBride WJ, D'Souza CA, Sharkey RM, et al. Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem. 2010;21:1331-1340.
32. McBride WJ, Sharkey RM, Karacay H, et al. A novel method of 18F radiolabeling for PET. J Nucl Med. 2009;50:991-998.
33. Liu S, Liu H, Jiang H, Xu Y, Zhang H, Cheng Z. One-step radiosynthesis of 18FAlF- NOTA-RGD2 for tumor angiogenesis PET imaging. Eur J Nucl Med Mol Imaging. 2011;38:1732-1741.
34. Jiang L, Kimura RH, Miao Z, et al. Evaluation of a 64Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin. J Nucl Med. 2010;51:251-258.
35. Yang M, Gao H, Zhou Y, et al. 18F-Labeled GRPR agonists and antagonists: a comparative study in prostate cancer imaging. Theranostics. 2011;1:220-229.
36. D'Souza CA, McBride WJ, Sharkey RM, Todaro LJ, Goldenberg DM. Highyielding aqueous 18F-labeling of peptides via Al18F chelation. Bioconjug Chem. 2011;22:1793-1803.
37. Schroeder RP, Muller C, Reneman S, et al. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging. 2010;37:1386-1396.
38. Dijkgraaf I, Franssen GM, McBride WJ, et al. PET of tumors expressing gastrinreleasing peptide receptor with an 18F-labeled bombesin Analog. J Nucl Med. 2012;53:947-952.